Avenue Therapeutics, Inc. (ATXI) Earnings History
Annual and quarterly earnings data from 2015 to 2024
Loading earnings history...
ATXI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ATXI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export ATXI earnings history in CSV or JSON format
Free sign-in required to download data
Avenue Therapeutics, Inc. (ATXI) Earnings Overview
As of May 7, 2026, Avenue Therapeutics, Inc. (ATXI) reported trailing twelve-month net income of -$4M, reflecting +98.8% year-over-year growth. The company earned $-1.18 per diluted share over the past four quarters.
Looking at the long-term picture, ATXI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2016.
Avenue Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PCRX ($9M net income, 1.0% margin), COLL ($63M net income, 8.1% margin), MNKD (-$24M net income, 1.7% margin), ATXI has comparable earnings metrics. Compare ATXI vs PCRX →
ATXI Earnings vs Peers
Earnings metrics vs comparable public companies
ATXI Historical Earnings Data (2015–2024)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$12M | -12.3% | -$11M | $-0.90 | - | - |
| 2023 | -$10M | -192.1% | -$15M | $-73.48 | - | - |
| 2022 | -$4M | +4.8% | -$8M | $-121.91 | - | - |
| 2021 | -$4M | +27.6% | -$4M | $-3.29 | - | - |
| 2020 | -$5M | +80.1% | -$5M | $-4.65 | - | - |
| 2019 | -$26M | -20.2% | -$26M | $-24.38 | - | - |
| 2018 | -$22M | -75.8% | -$22M | $-31.17 | - | - |
| 2017 | -$12M | -285.8% | -$11M | $-27.71 | - | - |
| 2016 | -$3M | +39.2% | -$2M | $-5.39 | - | - |
| 2015 | -$5M | - | -$5M | $-9.40 | - | - |
See ATXI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATXI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATXI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATXI — Frequently Asked Questions
Quick answers to the most common questions about buying ATXI stock.
Is ATXI growing earnings?
ATXI EPS is $-1.18, with earnings growth accelerating to +98.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-4M.
What are ATXI's profit margins?
Avenue Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ATXI's earnings?
ATXI earnings data spans 2015-2024. The accelerating earnings trend is +98.8% YoY. Historical data enables comparison across business cycles.